Theravance,
Inc. THRX (the "Company"), a biopharmaceutical company with
a pipeline of internally discovered product candidates and strategic
collaborations with pharmaceutical companies, announced that the
underwriters of its 2.125% convertible subordinated notes due 2023
(the "notes") have exercised in full their option to purchase an
additional $37.5 million aggregate principal amount of the notes, for
a total offering size of $287.5 million. The offering is scheduled to
close on Thursday, January 24, 2013, subject to satisfaction of
customary closing conditions. BofA Merrill Lynch is acting as the
sole book-running manager for the offering.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in